DK1689391T3 - 5-Phenyl-4-methyl-thiazol-2-yl-amin-derivater som inhibitorer af phosphatidylinositol-3-kinase-enzymer (P13) til behandling af betændelsessygdomme i luftvejene - Google Patents
5-Phenyl-4-methyl-thiazol-2-yl-amin-derivater som inhibitorer af phosphatidylinositol-3-kinase-enzymer (P13) til behandling af betændelsessygdomme i luftvejeneInfo
- Publication number
- DK1689391T3 DK1689391T3 DK04764560T DK04764560T DK1689391T3 DK 1689391 T3 DK1689391 T3 DK 1689391T3 DK 04764560 T DK04764560 T DK 04764560T DK 04764560 T DK04764560 T DK 04764560T DK 1689391 T3 DK1689391 T3 DK 1689391T3
- Authority
- DK
- Denmark
- Prior art keywords
- phosphatidylinositol
- thiazol
- inhibitors
- phenyl
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0320197.7A GB0320197D0 (en) | 2003-08-28 | 2003-08-28 | Organic compounds |
PCT/EP2004/009586 WO2005021519A2 (en) | 2003-08-28 | 2004-08-27 | 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1689391T3 true DK1689391T3 (da) | 2009-07-27 |
Family
ID=28686509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04764560T DK1689391T3 (da) | 2003-08-28 | 2004-08-27 | 5-Phenyl-4-methyl-thiazol-2-yl-amin-derivater som inhibitorer af phosphatidylinositol-3-kinase-enzymer (P13) til behandling af betændelsessygdomme i luftvejene |
Country Status (34)
Country | Link |
---|---|
US (3) | US7902375B2 (da) |
EP (1) | EP1689391B1 (da) |
JP (1) | JP4574618B2 (da) |
KR (1) | KR100774038B1 (da) |
CN (1) | CN1838953B (da) |
AR (1) | AR045510A1 (da) |
AT (1) | ATE429225T1 (da) |
AU (1) | AU2004268050B2 (da) |
BR (1) | BRPI0413934A (da) |
CA (1) | CA2533175A1 (da) |
CY (1) | CY1109227T1 (da) |
DE (1) | DE602004020793D1 (da) |
DK (1) | DK1689391T3 (da) |
EC (1) | ECSP066383A (da) |
ES (1) | ES2323000T3 (da) |
GB (1) | GB0320197D0 (da) |
HK (1) | HK1093688A1 (da) |
HR (1) | HRP20090340T1 (da) |
IL (1) | IL173035A0 (da) |
IS (1) | IS2690B (da) |
MA (1) | MA28007A1 (da) |
MX (1) | MXPA06002217A (da) |
MY (1) | MY135050A (da) |
NO (1) | NO20061406L (da) |
NZ (1) | NZ545139A (da) |
PE (1) | PE20050872A1 (da) |
PL (1) | PL1689391T3 (da) |
PT (1) | PT1689391E (da) |
RU (1) | RU2382783C2 (da) |
SI (1) | SI1689391T1 (da) |
TN (1) | TNSN06064A1 (da) |
TW (1) | TWI347941B (da) |
WO (1) | WO2005021519A2 (da) |
ZA (1) | ZA200600415B (da) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
WO2005118543A1 (ja) * | 2004-06-03 | 2005-12-15 | Ono Pharmaceutical Co., Ltd. | キナーゼ阻害薬およびその用途 |
WO2006037468A1 (en) * | 2004-09-30 | 2006-04-13 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv reverse transcriptase inhibitors |
ZA200710104B (en) | 2005-05-24 | 2009-03-25 | Serono Lab | Thiazole derivatives and use thereof |
US7799814B2 (en) | 2005-05-24 | 2010-09-21 | Merck Serono S.A. | Thiazole derivatives and use thereof |
EP1917252B1 (en) | 2005-08-26 | 2014-01-01 | Merck Serono SA | Pyrazine derivatives and use as pi3k inhibitors |
GB0525671D0 (en) * | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
EP1991528A2 (en) * | 2006-01-18 | 2008-11-19 | Siena Biotech S.p.A. | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
GB0608854D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | P13 kinase inhibitors |
GB0608823D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of P13 kinase |
GB0610243D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
GB0612630D0 (en) * | 2006-06-26 | 2006-08-02 | Novartis Ag | Organic compounds |
CN101663283B (zh) | 2007-02-22 | 2014-04-09 | 默克雪兰诺有限公司 | 喹喔啉化合物及其用途 |
CA2687964A1 (en) | 2007-06-01 | 2009-02-19 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
KR20100093129A (ko) | 2007-12-20 | 2010-08-24 | 노파르티스 아게 | Pi 3 키나제 억제제로서 사용되는 티아졸 유도체 |
WO2009080705A2 (en) * | 2007-12-20 | 2009-07-02 | Novartis Ag | Bis-thiazole derivatives, process for their preparation and their use as medicaments |
UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
CN101684106B (zh) * | 2008-09-22 | 2013-06-12 | 北京摩力克科技有限公司 | 噻唑鎓盐类化合物及其治疗蛋白老化相关疾病的用途 |
CA2751501C (en) | 2009-02-12 | 2018-01-16 | Merck Serono S.A. | 2-morpholino-pyrido[3,2-d]pyrimidines |
AU2010243613B2 (en) * | 2009-04-30 | 2015-05-07 | Glaxo Group Limited | Oxazole substituted indazoles as PI3-kinase inhibitors |
EP2440556A1 (en) * | 2009-06-10 | 2012-04-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatidylinositol 3-kinase |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
MX2012000178A (es) | 2009-07-02 | 2012-02-28 | Novartis Ag | 2-carboxamida-cicloamino-ureas utiles como inhibidores de pi3k. |
EP2492269A4 (en) | 2009-10-19 | 2013-08-07 | Taisho Pharmaceutical Co Ltd | aminothiazole |
EA201290305A1 (ru) | 2009-11-13 | 2012-12-28 | Мерк Сероно С.А. | Производные трициклического пиразоламина |
EP2531194B1 (en) | 2010-02-03 | 2018-04-18 | Signal Pharmaceuticals, LLC | Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors |
GB201018124D0 (en) * | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
WO2013018733A1 (ja) * | 2011-07-29 | 2013-02-07 | 富士フイルム株式会社 | 1,5-ナフチリジン誘導体又はその塩 |
WO2013019927A1 (en) | 2011-08-03 | 2013-02-07 | Signal Pharmaceuticals, Llc | Identification of gene expression profile as a predictive biomarker for lkb1 status |
EP2763532B1 (en) | 2011-10-05 | 2018-09-19 | The Board of Trustees of the Leland Stanford Junior University | Pi-kinase inhibitors with broad spectrum anti-infective activity |
US9926309B2 (en) | 2011-10-05 | 2018-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with anti-infective activity |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
NZ730189A (en) | 2013-04-17 | 2018-09-28 | Signal Pharm Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
KR102240356B1 (ko) | 2013-04-17 | 2021-04-14 | 시그날 파마소티칼 엘엘씨 | Tor 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법 |
AU2014254053B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Treatment of cancer with Dihydropyrazino-Pyrazines |
KR102221005B1 (ko) | 2013-04-17 | 2021-02-26 | 시그날 파마소티칼 엘엘씨 | 전립선암 치료를 위한 디하이드로피라지노-피라진 화합물 및 안드로겐 수용체 길항제를 포함하는 조합 요법 |
JP6382948B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ,エルエルシー | 癌を治療するためのtorキナーゼ阻害剤及びシチジン類似体を含む組合せ療法 |
BR112015026021A2 (pt) | 2013-04-17 | 2017-07-25 | Signal Pharm Llc | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer |
KR102271344B1 (ko) | 2013-04-17 | 2021-07-01 | 시그날 파마소티칼 엘엘씨 | 디하이드로피라지노-피라진을 사용한 암의 치료 |
WO2014193912A1 (en) | 2013-05-29 | 2014-12-04 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
EP3273955A4 (en) * | 2015-03-23 | 2019-05-01 | The University of Melbourne | TREATMENT OF RESPIRATORY DISEASES |
US10385019B2 (en) | 2015-06-30 | 2019-08-20 | Dana-Farber Cancer Institute, Inc. | Inhibitors of EGFR and methods of use thereof |
WO2017147526A1 (en) | 2016-02-26 | 2017-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with anti-infective activity |
JOP20190052A1 (ar) * | 2016-09-22 | 2019-03-21 | Astrazeneca Ab | 5-[2-(بيريدين-2-يلامينو )-3،1 ثيازول-5-يال]-3،2 – ثنائي هيدرو- 1h- إيزوإندول 1--مشتق واحد واستخدامها كمثبطات مزدوجة للدلتا وغاما فوسفاتيديلينوسيتول 3-كيناز |
SG11201912403SA (en) | 2017-06-22 | 2020-01-30 | Celgene Corp | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993000342A1 (en) * | 1991-06-21 | 1993-01-07 | Boehringer Mannheim Italia S.P.A. | 2-amino-4-aryl-thiazoles with antiasthmatic and anti-inflammatory activities on the respiratory tract |
GB9823873D0 (en) * | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
ATE309241T1 (de) | 1999-09-10 | 2005-11-15 | Merck & Co Inc | Tyrosin kinase inhibitoren |
US6667300B2 (en) * | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
JP2004516238A (ja) * | 2000-06-21 | 2004-06-03 | ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー | ケモカイン受容体活性調節剤としてのn−ウレイドアルキル−ピペリジン |
CN100457753C (zh) | 2000-07-26 | 2009-02-04 | 布里斯托尔-迈尔斯斯奎布公司 | 依赖细胞周期蛋白的激酶的n-[5-[[[5-烷基-2-唑基]甲基]硫代]-2-噻唑基]甲酰胺抑制剂 |
WO2003015778A1 (en) * | 2001-08-17 | 2003-02-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
AR038703A1 (es) | 2002-02-28 | 2005-01-26 | Novartis Ag | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 |
-
2003
- 2003-08-28 GB GBGB0320197.7A patent/GB0320197D0/en not_active Ceased
-
2004
- 2004-08-26 PE PE2004000820A patent/PE20050872A1/es not_active Application Discontinuation
- 2004-08-26 AR ARP040103072A patent/AR045510A1/es not_active Application Discontinuation
- 2004-08-26 TW TW093125599A patent/TWI347941B/zh not_active IP Right Cessation
- 2004-08-27 BR BRPI0413934-8A patent/BRPI0413934A/pt not_active IP Right Cessation
- 2004-08-27 US US10/568,053 patent/US7902375B2/en not_active Expired - Fee Related
- 2004-08-27 DE DE602004020793T patent/DE602004020793D1/de active Active
- 2004-08-27 DK DK04764560T patent/DK1689391T3/da active
- 2004-08-27 SI SI200431138T patent/SI1689391T1/sl unknown
- 2004-08-27 JP JP2006524337A patent/JP4574618B2/ja not_active Expired - Fee Related
- 2004-08-27 CN CN2004800237755A patent/CN1838953B/zh not_active Expired - Fee Related
- 2004-08-27 MY MYPI20043510A patent/MY135050A/en unknown
- 2004-08-27 WO PCT/EP2004/009586 patent/WO2005021519A2/en active Application Filing
- 2004-08-27 EP EP04764560A patent/EP1689391B1/en active Active
- 2004-08-27 NZ NZ545139A patent/NZ545139A/en not_active IP Right Cessation
- 2004-08-27 KR KR1020067004006A patent/KR100774038B1/ko not_active IP Right Cessation
- 2004-08-27 AU AU2004268050A patent/AU2004268050B2/en not_active Ceased
- 2004-08-27 MX MXPA06002217A patent/MXPA06002217A/es active IP Right Grant
- 2004-08-27 ES ES04764560T patent/ES2323000T3/es active Active
- 2004-08-27 CA CA002533175A patent/CA2533175A1/en not_active Abandoned
- 2004-08-27 AT AT04764560T patent/ATE429225T1/de active
- 2004-08-27 PL PL04764560T patent/PL1689391T3/pl unknown
- 2004-08-27 RU RU2006109545/04A patent/RU2382783C2/ru not_active IP Right Cessation
- 2004-08-27 PT PT04764560T patent/PT1689391E/pt unknown
-
2006
- 2006-01-09 IL IL173035A patent/IL173035A0/en unknown
- 2006-01-16 ZA ZA200600415A patent/ZA200600415B/en unknown
- 2006-02-17 EC EC2006006383A patent/ECSP066383A/es unknown
- 2006-02-27 TN TNP2006000064A patent/TNSN06064A1/en unknown
- 2006-02-27 MA MA28835A patent/MA28007A1/fr unknown
- 2006-03-24 IS IS8372A patent/IS2690B/is unknown
- 2006-03-28 NO NO20061406A patent/NO20061406L/no not_active Application Discontinuation
-
2007
- 2007-01-15 HK HK07100510.4A patent/HK1093688A1/xx not_active IP Right Cessation
-
2009
- 2009-06-12 HR HR20090340T patent/HRP20090340T1/xx unknown
- 2009-07-14 CY CY20091100743T patent/CY1109227T1/el unknown
-
2011
- 2011-02-03 US US13/020,211 patent/US20110124693A1/en not_active Abandoned
- 2011-02-03 US US13/020,247 patent/US20110124624A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1689391T3 (da) | 5-Phenyl-4-methyl-thiazol-2-yl-amin-derivater som inhibitorer af phosphatidylinositol-3-kinase-enzymer (P13) til behandling af betændelsessygdomme i luftvejene | |
DK1817282T3 (da) | Til behandling af respiratoriske sygdomme egnede phenoxy derivater | |
DK1708992T3 (da) | Sulfonamidderivater til behandling af sygdomme | |
DK1937633T3 (da) | Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme | |
DK1556342T3 (da) | Phenethanolaminderivat til behandling af respiratoriske sygdomme | |
DK1723136T3 (da) | Piperidinamino-benzimidazol-derivat som inhibitorer af replikation af respiratorisk syncytial virus | |
DK1656347T3 (da) | Substituerede indolderivater til farmaceutisk sammensætning til behandling af luftvejssygdomme | |
DK1425001T3 (da) | Phenethanolaminderivater til behandling af respiratoriske sygdomme | |
DK1471057T3 (da) | Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2 | |
IS7684A (is) | Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand | |
DK1708991T3 (da) | Sulfonamid derivater til behandling af sygdomme | |
DK1716162T3 (da) | Phosphonater, amidomonophosphonater, amidobisphosphonater til behandling af virussygdomme | |
DE502004008604D1 (de) | Pyrrolopyridin-substitutierte benzol-derivate zur behandlung kardiovaskulärer erkrankungen | |
DE602005023172D1 (de) | Hydantoinderivate zur behandlung von entzündlichen erkrankungen | |
DK1830843T3 (da) | Indolidon-derivater til behandling eller forebyggelse af fibrotiske sygdomme | |
LTC1781298I2 (lt) | Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui | |
DK1701941T3 (da) | Forbindelser til behandling af sygdomme med celleproliferation | |
DK1778673T3 (da) | Nye hydantoin-derivater til behandling af obstruktive luftvejssygdomme | |
DK1830850T3 (da) | Quinolin-derivater til behandling af latent tuberkulose | |
DK1420759T3 (da) | Farmaceutiske sammensætninger til behandling af astma | |
DK1701946T3 (da) | 1-piperazin- og 1-homopiperazincarboxylatderivater, deres fremstilling og deres terapeutiske anvendelse som inhibitorer af FAAH-enzymet | |
DE602005017503D1 (de) | Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen | |
NO20040356L (no) | Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling. | |
DK1856063T3 (da) | 5-phenyl-pentansyrederivater som matrix- metalloproteinaseinhibitorer til behandlingen af astma og andre sygdomme | |
DK1354597T3 (da) | Farmaceutisk kombination til behandling af vævsskader forårsaget af en arterieirrigationsdefekt |